Q&A NNI Symposium at WCPGHAN 2021 on “New generation of HMOs: From latest Research to Clinical Practice”

Summary

The NNI Symposium at WCPGHAN 2021 on “New generation of HMOs: From latest Research to Clinical Practice” presented pre-clinical data on HMOs and its impact on immune, gut and brain health and also on new avenues of potential future benefits  on the impact of early life HMOs exposure on later bone health and influence on allergic outcomes. It also approached the benefits of two key HMO: 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT) in healthy infants and in those with cow’s milk protein allergy (CMPA). Recent research on more HMOs was also a topic of this symposium, which presented a study demonstrating safety and tolerance of the first clinical trial with a blend of 5 HMOs.